Monica Bengus

537 total citations
20 papers, 389 citations indexed

About

Monica Bengus is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Monica Bengus has authored 20 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Monica Bengus's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Sarcoidosis and Beryllium Toxicity Research (5 papers) and Diabetes Treatment and Management (4 papers). Monica Bengus is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Sarcoidosis and Beryllium Toxicity Research (5 papers) and Diabetes Treatment and Management (4 papers). Monica Bengus collaborates with scholars based in Switzerland, Italy and United States. Monica Bengus's co-authors include Frank Gilberg, Klaus-Uwe Kirchgaessler, Sergio Harari, Wim Wuyts, Steven D. Nathan, Jürgen Behr, Athol U. Wells, Marlies Wijsenbeek, John L. Stauffer and Claudia Valenzuela and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and European Respiratory Journal.

In The Last Decade

Monica Bengus

19 papers receiving 381 citations

Peers

Countries citing papers authored by Monica Bengus

Since Specialization

Citations

This map shows the geographic impact of Monica Bengus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monica Bengus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monica Bengus more than expected).

Fields of papers citing papers by Monica Bengus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monica Bengus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monica Bengus. The network helps show where Monica Bengus may publish in the future.

Co-authorship network of co-authors of Monica Bengus

This figure shows the co-authorship network connecting the top 25 collaborators of Monica Bengus. A scholar is included among the top collaborators of Monica Bengus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monica Bengus. Monica Bengus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES 2024 ·Journal of Hypertension ·Andrea Havasi, Neha J. Pagidipati, George L. Bakris, Michael A. Weber, Monica Bengus, Shruti Daga, (unknown), (unknown), Ishir Bhan, Christopher B. Granger	4
2	Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice 2023 ·SHILAP Revista de lepidopterología ·Robyn H. Guymer, Clare Bailey, Voraporn Chaikitmongkol, Usha Chakravarthy, Varun Chaudhary, Robert P. Finger, Roberto Gallego‐Pinazo, (unknown), Susumu Ishida, (unknown), Mariacristina Parravano, José D. Luna, Steffen Schmitz-Valckenberg, Veeral Sheth, Eric H. Souied, (unknown), Frank Gilberg, Carl Glittenberg, Stefan Scheidl, Monica Bengus	3
3	A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease 2022 ·Respiratory Research ·Toby M. Maher, Courtney Schiffman, Michael Kreuter, Catharina C. Moor, Steven D. Nathan, Judit Axmann, Paula Belloni, Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Marlies Wijsenbeek	17
4	The 6-min walk test as a primary end-point in interstitial lung disease 2022 ·European Respiratory Review ·Sergio Harari, Athol U. Wells, Wim Wuyts, Steven D. Nathan, Klaus-Uwe Kirchgaessler, Monica Bengus, Jürgen Behr	30
5	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study 2021 ·Advances in Therapy ·Marlies Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T. Henry, Catharina C. Moor, (unknown), Alessandro Giuseppe Fois, Onofre Moran‐Mendoza, (unknown), (unknown), Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	9
6	PerFECT 2.0: A Web-Based Platform Designed to Facilitate and Support the Diagnosis of Patients with Idiopathic Pulmonary Fibrosis in Italy 2021 ·Pulmonary Therapy ·Carlo Vancheri, Monica Bengus, (unknown), (unknown), (unknown), Donato Lacedonia, M. Pasquali, Gaetano Rea, (unknown), Alessandro Sanduzzi, Sebastiano Emanuele Torrisi, Alberto Pesci	0
7	Baseline Biomarker Levels Correlate with Degree of Fibrosis in Early ILD, Unclassifiable ILD, IPF, Advanced IPF, and Systemic Sclerosis Clinical Trial Cohorts 2021 ·(unknown), (unknown), (unknown), (unknown), (unknown), Monica Bengus, (unknown)	1
8	STARLINER study, disease behaviour assessed by a wide range of parameters including patient-reported outcomes (PRO) results 2021 ·Elisabeth Bendstrup, Marlies Wijsenbeek, Claudia Valenzuela, Michael T. Henry, Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	1
9	STARLINER study; patients’ and doctors’ experiences with a digital eco-system 2021 ·Marlies Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T. Henry, Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	1
10	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial 2020 ·The Lancet Respiratory Medicine ·Jürgen Behr, Steven D. Nathan, Wim Wuyts, Nesrin Moğulkoç, Demosthenes Bouros, Κατερίνα Αντωνίου, Julien Guiot, Mordechai R. Kramer, Klaus-Uwe Kirchgaessler, Monica Bengus, Frank Gilberg, (unknown), Sergio Harari, Athol U. Wells	97
11	Primary results from the STARLINER study of disease behaviour in suspected ILD 2020 ·SPIRE - Sciences Po Institutional REpository ·Marlies Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T. Henry, Catharina C. Moor, S. Jouneau, Alessandro Giuseppe Fois, (unknown), (unknown), (unknown), Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	1
12	Interim analysis of patients with ILD enrolled in the STARLINER study 2019 ·Marlies Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T. Henry, Catharina C. Moor, S. Jouneau, Alessandro Giuseppe Fois, (unknown), (unknown), (unknown), Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	3
13	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management 2018 ·Advances in Therapy ·Johan Van Cleemput, Andrea Sonaglioni, Wim Wuyts, Monica Bengus, John L. Stauffer, Sergio Harari	19
14	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study 2018 ·Advances in Therapy ·Marlies Wijsenbeek, Elisabeth Bendstrup, Claudia Valenzuela, Michael T. Henry, Catharina C. Moor, Monica Bengus, (unknown), Frank Gilberg, Klaus-Uwe Kirchgaessler, Carlo Vancheri	16
15	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study – Rationale and study design 2018 ·Respiratory Medicine ·Jürgen Behr, Steven D. Nathan, Sergio Harari, Wim Wuyts, Klaus-Uwe Kirchgaessler, Monica Bengus, Frank Gilberg, Athol U. Wells	26
16	Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis 2018 ·European Respiratory Journal ·Kevin R. Flaherty, Charlene D. Fell, John T. Huggins, Hilario Nunès, Robert Sussman, Claudia Valenzuela, (unknown), John L. Stauffer, Frank Gilberg, Monica Bengus, Marlies Wijsenbeek	99
17	Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes 2015 ·American Heart Journal ·Erland Erdmann, Robert M. Califf, Hertzel C. Gerstein, Klas Malmberg, Luís M. Ruilope, Gregory G. Schwartz, Hans Wedel, (unknown), Marc Ditmarsch, Anders Svensson, Monica Bengus	25
18	Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized controlled trials 2015 ·Diabetes Obesity and Metabolism ·Sreenivasa Rao Kondapally Seshasai, R. L. Bennett, John R. Petrie, Monica Bengus, Steffan Ekman, Mark Dixon, Matthias Herz, John B. Buse, Kausik K. Ray	11
19	Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study) 2013 ·Obesity ·Priscilla Hollander, Ben Lasko, Anthony Barnett, Monica Bengus, (unknown), F. Xavier Pi‐Sunyer, R. Balena	25
20	Abstract 15282: Individual Participant Meta Analysis of the Cardiovascular Safety of Taspoglutide Among Individuals with Diabetes 2012 ·Circulation ·Kausik K. Ray, R. L. Bennett, John R. Petrie, Monica Bengus, Steffan Ekman, Mark Dixon, Matthias Herz, John B. Buse	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact